No insider trades in Sofgen Pharma (PRCWF) director Alberto Eguiguren Form 3

Rhea-AI Filing Summary

Sofgen Pharma S.A. director Alberto Eguiguren filed a Form 3 related to the company. The filing shows no reported buy, sell, acquisition, or disposition transactions, and no derivative positions, indicating a baseline insider ownership report without trading activity in this filing.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Derivative transactions: 0 transactions +2 more

5 metrics

Buy transactions 0 transactions transactionSummary buyCount and buyShares

Sell transactions 0 transactions transactionSummary sellCount and sellShares

Derivative transactions 0 transactions transactionSummary derivativeTransactionCount

Net buy/sell shares 0 shares transactionSummary netBuySellShares

Net buy/sell direction neutral transactionSummary netBuySellDirection

Key Terms

Form 3, reportingPersons, transactionSummary, derivativeTransactionCount, +1 more

5 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Eguiguren Alberto""

transactionSummary financial

""transactionSummary": { "buyCount": 0, "sellCount": 0"

derivativeTransactionCount financial

""derivativeTransactionCount": 0,"

netBuySellDirection financial

""netBuySellDirection": "neutral""

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Eguiguren Alberto

(Last) (First) (Middle)

11600 MIRAMAR PARKWAY, SUITE 300

(Street)

MIRAMAR FLORIDA 33025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

See Exhibit 24 - Power of Attorney.

No securities are beneficially owned.

	/s/ Freddy Andres Lozano Reyes, attorney-in-fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Sofgen Pharma (PRCWF) Form 3 filing show for Alberto Eguiguren?

The Form 3 shows Alberto Eguiguren as a director of Sofgen Pharma S.A. It reports no buy, sell, acquire, or dispose transactions and no derivative positions, indicating zero transactional activity in this specific insider ownership filing.

Are there any insider share purchases or sales in this Sofgen Pharma (PRCWF) Form 3?

No. The transaction summary in the Form 3 lists zero buy, sell, acquisition, disposition, gift, tax withholding, or restructuring transactions, and a net buy/sell direction labeled neutral for this reporting period.

Does the Sofgen Pharma (PRCWF) Form 3 disclose any derivative securities for Alberto Eguiguren?

No. The Form 3 derivative summary is empty, and derivativeTransactionCount is also zero. This indicates no options, warrants, or other derivative positions are reported for Alberto Eguiguren in this filing excerpt.

How many insider holding entries are shown in the Sofgen Pharma (PRCWF) Form 3?

The transactionSummary section reports zero holdingEntries. Combined with an empty transactions list, this means the provided Form 3 data does not detail specific share holdings or positions for the reporting person.

What is the overall net insider trading direction in this Sofgen Pharma (PRCWF) Form 3?

The filing’s transactionSummary shows netBuySellDirection as "neutral" with netBuySellShares equal to zero. This reflects that no insider purchases or sales were recorded in the reported data for this Form 3.